Chronic obstructive lung disease - Strategic Insights Report (Page 2)

Diseases

New Research on Chronic Obstructive Pulmonary Disease Uses High-Resolution Mass Spectrometry to Identify Potential Biomarkers

Researchers at Henan University of Chinese Medicine have made a breakthrough in identifying potential biomarkers for the diagnosis of chronic obstructive pulmonary disease (COPD) using high-resolution mass spectrometry (HRMS). The study, published in the Journal of Chromatography B-analytical Technologies In the Biomedical and Life Sciences, used a method called pseudotargeted

Mortality

Chronic Obstructive Pulmonary Disease Linked to Higher Risk of Death from Cardiovascular Disease

Data from Japan has been presented, highlighting a strong correlation between chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD). Researchers from Jikei University and other institutions have uncovered a shared risk factor for both conditions, with the prevalence of each disease increasing with age. The study emphasizes the need

Diseases

Prevalence of Pseudomonas aeruginosa Colonization in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) affects millions worldwide, with a significant portion of patients colonized with Pseudomonas aeruginosa. Research has shown a strong association between prior exposure to antibiotics and inhaled corticosteroids and increased risk of PA colonization. A recent study conducted by researchers from Tianjin Medical University General Hospital

Diseases

Associations Between IL-13 Gene Polymorphism (rs20541) and Chronic Inflammatory Diseases

Research from Sunway University has associated a specific single nucleotide polymorphism (SNP) of the interleukin-13 (IL-13) gene, rs20541, with multiple chronic inflammatory diseases. While rs20541 has been linked to various immune-related conditions, its precise functional relevance in disease pathogenesis remains unclear. A meta-analysis of 45 case-control studies revealed consistent associations

Diseases

Delayed Diagnosis and Inadequate Care Contribute to Poor Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients

Research conducted at the Maharani Laxmi Bai Medical College in Jhansi, Uttar Pradesh, India, has highlighted the significant challenges faced by patients with chronic obstructive pulmonary disease (COPD) in seeking timely and adequate care. The study, published in the Asian Journal of Medical Sciences, found that most COPD patients rely

Diseases

New Study Reveals Correlation Between NLR, RDW, and Pulmonary Hypertension in BCOS Patients

A recent study published in The Clinical Respiratory Journal has shed light on the relationship between neutrophil to lymphocyte ratio (NLR), red blood cell distribution width (RDW), and pulmonary hypertension (PH) in patients with bronchiectasis and chronic obstructive pulmonary disease overlap syndrome (BCOS). The research, conducted by a team of

Diseases

Inadequate Palliative Care for Non-Oncological Patients

Patients with chronic conditions such as chronic obstructive pulmonary disease (COPD), dementia, and amyotrophic lateral sclerosis (ALS) often receive substandard palliative care compared to those with cancer, a recent study has shown. The research, conducted in Germany, analyzed claims data from 2016 to 2019 and found that non-oncological patients in

Diseases

New Study Reveals Promising Results for Zephyr Valve Treatment in Severe Emphysema

A systematic review and meta-analysis published in the Annals of Medicine & Surgery has found that the Zephyr valve treatment may improve lung function, exercise capacity, and quality of life for patients suffering from severe emphysema. The study, conducted by a team of researchers from the Department of Medicine at

Diseases

AstraZeneca's Fasenra Falls Short in RESOLUTE Phase III Trial for Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca's Fasenra, a treatment for chronic obstructive pulmonary disease (COPD), has failed to meet statistical significance in the primary endpoint of the RESOLUTE Phase III trial. Despite this setback, Fasenra remains a leading treatment for severe eosinophilic asthma (SEA) in over 80 countries, including the US, Japan, EU,

Diseases

AstraZeneca's Fasenra Trial Falls Short in COPD Treatment

AstraZeneca's flagship treatment, Fasenra (benralizumab), has shown promise in treating various respiratory diseases, but its latest trial, RESOLUTE, failed to demonstrate statistical significance in treating chronic obstructive pulmonary disease (COPD). The trial showed numerical improvement, but the results were not enough to meet the primary endpoint. Despite this

Diseases

Chronic Obstructive Pulmonary Disease Pipeline Outlook 2025: Emerging Therapies and Clinical Developments

A comprehensive pipeline report provides insights into the rapidly evolving landscape of Chronic Obstructive Pulmonary Disease (COPD) treatment, with over 65 companies and 70+ emerging therapies in various stages of development. The report highlights promising pipeline drugs, clinical trials, and market opportunities, offering a valuable resource for stakeholders in the

Diseases

Wildfire Smoke Exposure Linked to Respiratory Diseases

Wildfire smoke poses a significant threat to both individual and public health, contributing to increased morbidity, mortality, and socio-economic costs. A recent review of emerging evidence suggests that short-term exposure to wildfire smoke is associated with acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD), and pneumonia, resulting in increased

See all